- Conditions
- Neoplasms
- Interventions
- BI 1387446 50 μg, BI 754091, BI 1387446 100 μg, BI 1387446 200 μg, BI 1387446 400 μg
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 42 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2024
- U.S. locations
- 2
- States / cities
- Chapel Hill, North Carolina • Milwaukee, Wisconsin
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 433–456
of 1,062
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Neoplasms
- Interventions
- feladilimab, Tremelimumab, Docetaxel, Paclitaxel, Cetuximab
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 26 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2021
- U.S. locations
- 5
- States / cities
- Boston, Massachusetts • New York, New York • Pittsburgh, Pennsylvania + 1 more
- Conditions
- Solid Tumor, Adult, Colorectal Cancer, Pancreatic Ductal Adenocarcinoma
- Interventions
- CT3001, FOLFOX (5-fluorouracil, Leucovorin, Oxaliplatin)
- Drug
- Lead sponsor
- Crossignal Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 78 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Breast Cancer
- Interventions
- suberoylanilide hydroxamic acid (SAHA, Vorinostat), tamoxifen citrate (Tamoxifen)
- Drug
- Lead sponsor
- H. Lee Moffitt Cancer Center and Research Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 43 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2012
- U.S. locations
- 8
- States / cities
- San Francisco, California • Boynton Beach, Florida • Orlando, Florida + 5 more
- Conditions
- Colorectal Cancer
- Interventions
- Simtuzumab, Placebo to match SIM, Leucovorin, Irinotecan, Fluorouracil
- Biological · Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 266 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2015
- U.S. locations
- 56
- States / cities
- Huntsville, Alabama • Gilbert, Arizona • Alhambra, California + 49 more
- Conditions
- Colorectal Cancer
- Interventions
- FOLFIRI, RO5083945, cetuximab
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 169 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2013
- U.S. locations
- 16
- States / cities
- Encinitas, California • Highland, California • La Jolla, California + 11 more
- Conditions
- Advanced Solid Tumors
- Interventions
- ASP1948, nivolumab, pembrolizumab
- Drug
- Lead sponsor
- Astellas Pharma Global Development, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 190 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2023
- U.S. locations
- 17
- States / cities
- New Haven, Connecticut • Louisville, Kentucky • Baltimore, Maryland + 13 more
- Conditions
- Hepatitis C, Chronic
- Interventions
- Peginterferon alfa-2a, Ribavirin
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 63 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2007
- U.S. locations
- 12
- States / cities
- Birmingham, Alabama • Kansas City, Kansas • New Orleans, Louisiana + 9 more
- Conditions
- Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis
- Interventions
- Revumenib, Ruxolitinib, FEDRATINIB, Momelotinib
- Drug
- Lead sponsor
- John Mascarenhas
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 32 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Uveal Melanoma
- Interventions
- AEB071, BYL719
- Drug
- Lead sponsor
- Columbia University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2018
- U.S. locations
- 3
- States / cities
- Miami, Florida • New York, New York
- Conditions
- Multiple Myeloma
- Interventions
- Lenalidomide, Lenalidomide 25 MG Oral Capsule
- Drug
- Lead sponsor
- Starton Therapeutics, Inc
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2028
- U.S. locations
- 2
- States / cities
- Wilson, North Carolina • Canton, Ohio
- Conditions
- Solid Tumor
- Interventions
- Cetuximab, Carboplatin, 5 - FU
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 34 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2015
- U.S. locations
- 6
- States / cities
- Fayetteville, Arkansas • Fairway, Kansas • Portland, Oregon + 2 more
- Conditions
- Metastatic Breast Cancer
- Interventions
- PLX3397, Eribulin
- Drug
- Lead sponsor
- Hope Rugo, MD
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 67 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2019
- U.S. locations
- 3
- States / cities
- San Francisco, California • Durham, North Carolina • Nashville, Tennessee
- Conditions
- Pancreatic Cancer
- Interventions
- TTI-101, Stereotactic body radiation therapy
- Drug · Radiation
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2029
- U.S. locations
- 2
- States / cities
- Aurora, Colorado • St Louis, Missouri
- Conditions
- Chronic Hepatitis C
- Interventions
- BMS-790052, BMS-650032, Pegylated-interferon alfa-2a, Ribavirin
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 215 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2014
- U.S. locations
- 10
- States / cities
- Anaheim, California • Coronado, California • San Jose, California + 7 more
- Conditions
- Colorectal Cancer
- Interventions
- bevacizumab, fluorouracil, leucovorin calcium, oxaliplatin, conventional surgery, radiation therapy
- Biological · Drug · Procedure + 1 more
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 35 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2014
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Recurrent Malignant Glioma, Brain Glioblastoma
- Interventions
- OKN-007, Temozolomide (TMZ)
- Drug
- Lead sponsor
- Oblato, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 57 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2025
- U.S. locations
- 13
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Santa Monica, California + 10 more
- Conditions
- Metastatic Colorectal Cancer
- Interventions
- FOLFIRI, AMG 655, Placebo, AMG 479
- Other · Biological
- Lead sponsor
- NantCell, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 155 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2012
- U.S. locations
- 28
- States / cities
- Beverly Hills, California • Los Angeles, California • Santa Maria, California + 23 more
- Conditions
- Colorectal Cancer
- Interventions
- Tivozanib, Bevacizumab, mFOLFOX6
- Drug
- Lead sponsor
- AVEO Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 265 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2015
- U.S. locations
- 27
- States / cities
- Gilbert, Arizona • Hot Springs, Arizona • Tucson, Arizona + 22 more
- Conditions
- Carcinoma, Renal Cell
- Interventions
- Pembrolizumab, MK-4830, Belzutifan, Lenvatinib, Pembrolizumab/Quavonlimab, Favezelimab/Pembrolizumab
- Biological · Drug
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 263 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2026
- U.S. locations
- 11
- States / cities
- San Francisco, California • New Haven, Connecticut • Chicago, Illinois + 7 more
- Conditions
- Unspecified Adult Solid Tumor - Protocol Specific, Breast Cancer - Female
- Interventions
- Pazopanib, Paclitaxel, Carboplatin
- Drug
- Lead sponsor
- Rutgers, The State University of New Jersey
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 34 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2016
- U.S. locations
- 1
- States / cities
- New Brunswick, New Jersey
- Conditions
- Breast Cancer
- Interventions
- Hyperbaric Oxygen Therapy, Trental Pill, Vitamin E
- Procedure · Drug · Dietary Supplement
- Lead sponsor
- Legacy Health System
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2023
- U.S. locations
- 1
- States / cities
- Portland, Oregon
- Conditions
- Colorectal Cancer, Colorectal Neoplasms, Colorectal Carcinoma, Colorectal Tumors, Neoplasms, Colorectal
- Interventions
- NUC-3373 + leucovorin, NUC-3373, NUFOX, NUFOX + VEGF pathway inhibitor, NUFOX + EGFR inhibitor, NUFIRI, NUFIRI + VEGF pathway inhibitor, NUFIRI + EGFR inhibitor, NUC-3373 + bevacizumab
- Drug
- Lead sponsor
- NuCana plc
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 111 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2024
- U.S. locations
- 6
- States / cities
- Boston, Massachusetts • Durham, North Carolina • Nashville, Tennessee + 2 more
- Conditions
- Chronic Myeloid Leukemia
- Interventions
- RAD001, Imatinib
- Drug
- Lead sponsor
- University of Michigan Rogel Cancer Center
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2017
- U.S. locations
- 1
- States / cities
- Ann Arbor, Michigan